Accolade — Q4 2022 Earnings Presentation
29 slides from Accolade's earnings presentation, Apr 28, 2022
Slide 1: Accolade Investor Presentation
Accolade Investor Presentation
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: Our Mission and Vision
Our Mission Our mission is to empower people through expertise, empathy, and technology to make the best decisions for their health and well-being. Our Vision Our vision is every person living their healthiest life. 3
Slide 4: We Believe Relationships Matter
rN We believe relationships matter /. healthcare is for everyone © in value-based care in whole-person care
Slide 5: The Cost of a Poor Healthcare Experience
The Cost of a 76% Poor Healthcare of people don’t understand their available Experience benefits or how they work 88% of workers reported extreme stress, compared to 16% before the onset of COVID $225.88B in lost workforce productivity due to poor healthcare and preventable chronic conditions cost U
Slide 6: The Healthcare System Isn't Designed for Experience
The healthcare system isn’t designed for experience. The healthcare we have The healthcare we need need Transactional Holistic Disempowering Human centered Opaque Inclusive Biased Data driven and personalized Wasteful Value based 6
Slide 7: Welcome to Personalized Healthcare
Welcome to Personalized Healthcare This is the future of healthcare, and the future is now. Personal | Data Driven | Value Based 7
Slide 8: Personalized Healthcare
Personalized Healthcare Personal | Data Driven | Value Based 8
Slide 9: Delivering Value Across the Entire Healthcare Journey
Delivering Value Across the Entire Healthcare Journey Benefits Education, Utilization and Engagement Provider Selection, Care Delivery and Support Annual Open Enrollment Schedule appointment Verify benefits Address medical Research bills and ongoing Engage in care plan options treatment costs manage
Slide 10: A Truly Powerful, Personalized Healthcare Platform
A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based Accolade Accolade Accolade Accolade Advocacy Expert MD Care One Personalized, trusted Real-time expert Same-day access to Value-based care that guidance and education consultations for virtual primary and deeply
Slide 11: A Truly Powerful, Personalized Healthcare Platform
A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based 24/7 Care Team. Care EQ. True Health Engine. True Health It’s a long-term Building trust. The right data. Action Plan. relationship. The right next steps. 11
Slide 12: Engaging the Ecosystem
Engaging the Ecosystem Connecting members to the right program, at the right time, in the right way * Tuition Reimbursement Apps and EAP Portals Travel Insurance PBMs 401k Wellness and Health Optimizers Discount Benefits Programs Telehealth and Admin 2nd Opinion 12 13
Slide 13: Quadruple Aim
Quadruple Aim Better Patient Outcomes Satisfaction At Accolade, we’re improving clinical outcomes, lowering healthcare costs, improving patient satisfaction, and improving care team Reduced Physician Costs Experience and clinician satisfaction. 13
Slide 14: The Future
The Future
Slide 15: Accelerating Accolade's Clinical Innovation
Accelerating Accolade’s Clinical Innovation Lowering Healthcare Spend 2021 SEPTEMBER Introduced Personalized JUNE Healthcare – Accolade One 2020 Added PlushCare - and Accolade Care MARCH Virtual Primary Care Added 2nd.MD - SEPTEMBER Expert Medical 2007 - 2019 Launched Mental Opinion Health Integrate
Slide 16: Significantly Expanded Addressable Market $216 billion
Significantly Expanded Addressable Market $216 billion TAM 700 Customers 600+ $170B 600 Primary Care 500 400+ 400 300 200 $22B 112 Expert Medical Opinion 100 54 15 20 0 $24B 19 18 ) 20 22 21 D 20 20 20 M 20 20 Navigation & Advocacy nd FY FY FY FY FY /2 (w 21 20 FY 16
Slide 17: Compelling Growth Strategy
Compelling Growth Strategy Grow customer base Further penetrate our market of 30,000+ self- and fully insured employers Retain and expand Grow relationships especially through the sale of add-on services such as Virtual Primary Care and Expert Medical customer Opinion relationships Leverage machine
Slide 18: Financials
Financials 18
Slide 19: Financial Highlights
Financial Highlights ARR Bookings & new offerings driving substantial revenue growth 30% pro forma revenue growth FY21 to FY22; Ended FY22 with $286mm ACV; Growing DTC business PMPM recurring revenue model provides significant revenue visibility Multi-year contracts with base + performance-based PMP
Slide 20: Strong Revenue Growth
Strong Revenue Growth Predictable, highly visible, and recurring revenue Revenue and FYE ACV Quarterly Revenue $ millions $ millions $310.0 Revenue ACV at FYE $100 FY20 FY21 FY22 $93.8 $300 $286 $90 * $ 83.5 A GR $250 % C $80 $ 73.3 + 3 0 A GR $211 $70 %C $200 +3 3 $ 59.5 $59.2 $170.4 $60 $161 $150
Slide 21: Annual Result Trends
Annual Result Trends Revenue Adjusted Gross Profit and Adjusted Gross Profit Margin $310.0 M $144.2 mm $170.4 M $132.5 M $77.6 mm $94.8 M $59.1 mm $34.5 mm 44.6% 45.6% 46.5% 36.4% FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Adjusted EBITDA (Loss)* Adjusted Operating Expenses (as % of revenue) as a % of
Slide 22: Revenue and Customer Growth Drive Path to Profitability
Revenue and Customer Growth + Unit Economics Drive Path to Profitability * ~20% annual revenue growth Revenue vs Adjusted EBITDA (Loss) as a % of Revenue* ($ in millions) ~$500 $350 - $365 $310 $170 $133 $77 $95 0% - 3% (10-11)% (4-5)% (16)% (13)% (25)% (41)% (56)% FY18 FY19 FY20 FY21 FY22 FY23 FY24
Slide 23: Financial Targets and Goals
Financial Targets and Goals (Non-GAAP) Long-Term Goals Commentary Investments in technology and offering mix projected to drive GM% Adj. Gross Margin 50-55% up P&T as Projecting to continue to increase absolute dollar investments in % of Rev. 13-17% Product & Tech at a decreasing rate Adj. As sales
Slide 24: Appendix
Accolade Appendix
Slide 25: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and other expenses. We define Adjust
Slide 26: Adjusted EBITDA GAAP to Non-GAAP Reconciliation
Adjusted EBITDA (Loss) GAAP to Non-GAAP Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2018 2019 2020 2021 2022 Net Income (Loss) $ (61,286) $ (56,496) $ (51,365) $ (50,652) $ (123,124) Adjusted for: Interest expense, net 1,799 2,374 2,925 3,724 2,905 Income tax expense (benefit
Slide 27: Adjusted Gross Margin GAAP to Non-GAAP Reconciliation
Adjusted Gross Margin GAAP to Non-GAAP Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 Less: Cost of revenue, excluding depreciation and (60,568) (73,685) (93,673) (169,019) amortization Gross Profit, excluding de
Slide 28: Adjusted Operating Expense Reconciliation
Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 Operating Expenses 88,220 107,026 123,462 266,727 Less: Depreciation and amortization (9,391) (8,516) (8,212) (42,608) Stock-based compens
Slide 29: Accolade
Accolade PERSONALIZED HEALTHCARE